Precision Therapies
00_Home.
Revolutionising Cancer Treatment.
01_Platform.
Odysseus Platform.
Through our proprietary gene therapy platform, Odysseus, we’re uniquely positioned to develop precision cancer treatments that selectively target diseased cell states and behaviour, combining payloads that reveal cancer to the body’s immune system and kill tumour cells.
02_Approach.
Precision Therapies.
Our approach allows for selective treatment of cancer cells without toxicity to healthy tissue.
Like a Trojan horse, our therapy hides within the tumour, awakening the immune system and offering long-term protection against recurrence.
This potentially offers a paradigm shift from chronic disease management to one-time curative therapies.
03_Science.
Synthetic Super-Enhancers (SSEs).
The Key to Precision.
We’re revolutionising cancer treatment through our innovative Synthetic Super-Enhancers (SSEs) technology.
These SSEs are engineered DNA elements that are only activated in diseased cell states.
SSEs act as docking stations for transcription factors uniquely expressed in aggressive cancer or diseased cells, allowing for highly selective and potent gene control.
_Discover.
Our Breakthrough Technology.
Our viral immunotherapy technology uses highly specific SSEs, activated only in aggressive cancer cells, to control the expression of two therapeutic payloads within an AAV vector system.
The payloads work in tandem: one produces an enzyme converting an oral prodrug into a cytotoxic agent, while the other generates IL-12 to stimulate an immune response against the tumour.
The therapy is injected directly into the tumour via an AAV vector, the Trojan Horse, which not only eliminates the primary tumour but also establishes long-term immune memory preventing tumour regrowth.
(MoA animation by Visual Science, 2024)
Trogenix has developed a robust pipeline of potentially curative therapies for multiple cancer types, beginning with glioblastoma (GBM).
This diverse pipeline leverages the versatility of our SSE technology, allowing us to rapidly adapt our approach to different cancer types. We are also developing potential applications beyond oncology, such as regenerative medicine.
04_Programme.
Glioblastoma_Our Lead Programme.
Our lead programme is in glioblastoma (GBM), one of the most aggressive forms of brain cancer and an area of extremely high unmet medical need.
Current treatments offer limited efficacy.
Affects
200,000
GBM affects approximately two hundred thousand people globally each year.
Incidence
25
Only twenty five percent of patients survive beyond one year.
Overall
15
With a median overall survival of just fifteen months.
After decades of intensive research, we finally have the advanced tools and deep understanding necessary to tackle this formidable challenge.
Trogenix’s GBM therapy has shown curative potential in preclinical studies, demonstrating –
- Complete responses with no toxicity and no relapse
- Potent innate and adaptive immune responses
- Evidence of persistent anti-tumour immunity
- Efficacy in late-stage tumours reflecting real-world clinical presentation
- Validation of transduction and expression in patient tumour tissue
05_Team.
Founding Team.
Founded in 2023 by world-renowned experts, we’re on a mission to transform cancer treatment paradigms, offering hope where traditional therapies fall short.
06_News.
Latest News.
